Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver, affecting around 35% of the world population. Various circumstances contribute to the initiation and progression of NAFLD, and it encompasses a wide range of disorders, from simple steatosis to nonalcoholic...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2022/5805398 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562222477344768 |
|---|---|
| author | Ali Mahmoudi Seyed Adel Moallem Thomas P. Johnston Amirhossein Sahebkar |
| author_facet | Ali Mahmoudi Seyed Adel Moallem Thomas P. Johnston Amirhossein Sahebkar |
| author_sort | Ali Mahmoudi |
| collection | DOAJ |
| description | Nonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver, affecting around 35% of the world population. Various circumstances contribute to the initiation and progression of NAFLD, and it encompasses a wide range of disorders, from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Although several treatments have been proposed, there is no definitive cure for NAFLD. In recent decades, several medications related to other metabolic disorders have been evaluated in preclinical studies and in clinical trials due to the correlation of NAFLD with other metabolic diseases. Fenofibrate is a fibrate drug approved for dyslipidemia that could be used for modulation of hepatic fat accumulation, targeting peroxisome proliferator-activator receptors, and de novo lipogenesis. This drug offers potential therapeutic efficacy for NAFLD due to its capacity to decrease the accumulation of hepatic lipids, as well as its antioxidant, anti-inflammatory, and antifibrotic properties. To better elucidate the pathophysiological processes underlying NAFLD, as well as to test therapeutic agents/interventions, experimental animal models have been extensively used. In this article, we first reviewed experimental animal models that have been used to evaluate the protective effects of fenofibrate on NAFLD/NASH. Next, we investigated the impact of fenofibrate on the hepatic microcirculation in NAFLD and then summarized the beneficial effects of fenofibrate, as compared to other drugs, for the treatment of NAFLD. Lastly, we discuss possible adverse side effects of fenofibrate on the liver. |
| format | Article |
| id | doaj-art-d27065c2ab9743549d2843ebd4f5d542 |
| institution | Kabale University |
| issn | 1687-4765 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-d27065c2ab9743549d2843ebd4f5d5422025-02-03T01:23:09ZengWileyPPAR Research1687-47652022-01-01202210.1155/2022/5805398Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal ModelsAli Mahmoudi0Seyed Adel Moallem1Thomas P. Johnston2Amirhossein Sahebkar3Student Research CommitteeDepartment of Pharmacology and ToxicologyDivision of Pharmacology and Pharmaceutical SciencesApplied Biomedical Research CenterNonalcoholic fatty liver disease (NAFLD) is initiated by excessive fat buildup in the liver, affecting around 35% of the world population. Various circumstances contribute to the initiation and progression of NAFLD, and it encompasses a wide range of disorders, from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer. Although several treatments have been proposed, there is no definitive cure for NAFLD. In recent decades, several medications related to other metabolic disorders have been evaluated in preclinical studies and in clinical trials due to the correlation of NAFLD with other metabolic diseases. Fenofibrate is a fibrate drug approved for dyslipidemia that could be used for modulation of hepatic fat accumulation, targeting peroxisome proliferator-activator receptors, and de novo lipogenesis. This drug offers potential therapeutic efficacy for NAFLD due to its capacity to decrease the accumulation of hepatic lipids, as well as its antioxidant, anti-inflammatory, and antifibrotic properties. To better elucidate the pathophysiological processes underlying NAFLD, as well as to test therapeutic agents/interventions, experimental animal models have been extensively used. In this article, we first reviewed experimental animal models that have been used to evaluate the protective effects of fenofibrate on NAFLD/NASH. Next, we investigated the impact of fenofibrate on the hepatic microcirculation in NAFLD and then summarized the beneficial effects of fenofibrate, as compared to other drugs, for the treatment of NAFLD. Lastly, we discuss possible adverse side effects of fenofibrate on the liver.http://dx.doi.org/10.1155/2022/5805398 |
| spellingShingle | Ali Mahmoudi Seyed Adel Moallem Thomas P. Johnston Amirhossein Sahebkar Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models PPAR Research |
| title | Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models |
| title_full | Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models |
| title_fullStr | Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models |
| title_full_unstemmed | Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models |
| title_short | Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models |
| title_sort | liver protective effect of fenofibrate in nash nafld animal models |
| url | http://dx.doi.org/10.1155/2022/5805398 |
| work_keys_str_mv | AT alimahmoudi liverprotectiveeffectoffenofibrateinnashnafldanimalmodels AT seyedadelmoallem liverprotectiveeffectoffenofibrateinnashnafldanimalmodels AT thomaspjohnston liverprotectiveeffectoffenofibrateinnashnafldanimalmodels AT amirhosseinsahebkar liverprotectiveeffectoffenofibrateinnashnafldanimalmodels |